Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifeprunox versus placebo for psychosis and behavioral disturbances in elderly patients with Alzheimer's-type dementia
2005-003475-20Phase 3Terminated
- Sponsor
- Solvay Pharmaceuticals
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Bifeprunox with Placebo (2 arms). Primary endpoints: Change from baseline to endpoint in Brief Psychiatric Rating Scale and Safety and tolerability. Started Apr 2006; status: terminated.
02
Drugs
bifeprunox
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2005-003475-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003475-20.